These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9838558)

  • 1. Effects of calcium channel blockers in renal allograft patients receiving cyclosporine.
    Suh BY; Kwun OS; Kwun KB
    Transplant Proc; 1998 Nov; 30(7):3558-60. PubMed ID: 9838558
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study.
    Kuypers DR; Neumayer HH; Fritsche L; Budde K; Rodicio JL; Vanrenterghem Y;
    Transplantation; 2004 Oct; 78(8):1204-11. PubMed ID: 15502721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 4. Study of neoral kinetics in adult renal transplantation treated with diltiazem.
    Mezzano S; Flores C; Ardiles L; Foradori A; Elberg A
    Transplant Proc; 1998 Aug; 30(5):1660-2. PubMed ID: 9723232
    [No Abstract]   [Full Text] [Related]  

  • 5. Lower incidence of liver graft rejection in patients on diltiazem plus cyclosporine therapy.
    Mies S; Massarollo PC; Figueira ER; Leitão RM; Raia S
    Transplant Proc; 1998 Jun; 30(4):1437-8. PubMed ID: 9636582
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term beneficial effects of a nifedipine-supplemented immunosuppressive regimen in kidney transplantation.
    Shin GT; Cheigh JS; Riggio RR; Suthanthiran M; Stubenbord WT; Serur D; Wang JC; Rubin A; Stenzel KH
    Transplant Proc; 1996 Jun; 28(3):1309-10. PubMed ID: 8658672
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival.
    Markell MS; Homel P; Sumrani N; Hong JH; Distant DA; Miles AM; Sommer BG; Friedman EA
    Transplant Proc; 1998 Aug; 30(5):1980-2. PubMed ID: 9723360
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
    Park K; Kim MS; Kim SI; Kim YS; Moon JI
    Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
    [No Abstract]   [Full Text] [Related]  

  • 9. Variability of Sandimmune pharmacokinetics in renal transplant patients.
    Wingerchuk C; Heim-Duthoy KL; Macres MG; Kasiske BL
    Transplant Proc; 1998 Aug; 30(5):1656-7. PubMed ID: 9723230
    [No Abstract]   [Full Text] [Related]  

  • 10. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
    Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
    Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of hypertension, hyperlipidemia and cyclosporine A therapy on long-term renal allograft survival.
    Maeda H; Sakamoto K; Kashiwabara H; Hachisu T; Yamada H; Matsushita K; Yamada K; Yokoyama T
    Transplant Proc; 1996 Jun; 28(3):1633-4. PubMed ID: 8658816
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of nicardipine on blood cyclosporine levels in renal transplant patients.
    Guan D; Wang R; Lu J; Wang M; Xu C
    Transplant Proc; 1996 Jun; 28(3):1311-2. PubMed ID: 8658673
    [No Abstract]   [Full Text] [Related]  

  • 13. Trial of steroid withdrawal in renal transplant recipients with long-term--surviving allograft.
    Mizuno Y; Kikuchi H; Fujimori K; Doi H; Orii T; Ohkohchi N; Satomi S
    Transplant Proc; 2000 Nov; 32(7):1677-8. PubMed ID: 11119888
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoral reduces the incidence of acute rejection after renal transplantation.
    Sandrini S; Setti G; Gaggia P; Chiappini R; Maffeis R; Tardanico R; Maiorca R
    Transplant Proc; 1998 Aug; 30(5):1758-9. PubMed ID: 9723269
    [No Abstract]   [Full Text] [Related]  

  • 15. Allograft instability with frequent acute rejections and early chronic transplant glomerulopathy related to suboptimal doses of cyclosporine A.
    Savin M; Petronic V; Djukanovic L; Dujic A; Stojkovic D; Sindjic M
    Transplant Proc; 1997 Nov; 29(7):2977-9. PubMed ID: 9365636
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoral versus Sandimmune in kidney transplantation.
    Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
    Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
    [No Abstract]   [Full Text] [Related]  

  • 17. Early cyclosporine concentration as predictor of graft survival in cadaveric renal transplantation.
    Salmela K; Kyllönen L
    Transplant Proc; 2001 Jun; 33(4):2441-3. PubMed ID: 11406202
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of subclinical rejection on renal allograft histology and function at 6 months.
    Rush D; Jeffery J; Trpkov K; Solez K; Gough J
    Transplant Proc; 1996 Feb; 28(1):494-5. PubMed ID: 8644325
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection.
    Behrend M; Lueck R; Pichlmayr R
    Transplant Proc; 1997 Nov; 29(7):2927-9. PubMed ID: 9365617
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
    Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.